[7] reported that plasma NT-proBNP levels were a risk factor for adverse kidney outcomes (the composite of halving eGFR or initiating kidney replacement therapy) in nondiabetic CKD patients (HR ≥ 1.5) and in diabetic CKD patients (HR ≥ 2.0) among 3379 CKD participants (47% participants with concomitant diabetes). This evidence concerns the gene NPPB and chronic kidney disease.